Previous 10 | Next 10 |
First-Ever Off-The-Shelf Allogeneic T-Cell Therapy to be Reviewed by any Regulatory Agency in the World EMA Priority Medicines (PRIME) and Orphan Designated Tabelecleucel One Step Closer for Patients with High Unmet Need EU Approval Decision Anticipated for Second Half...
The following slide deck was published by Atara Biotherapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Atara Biotherapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Seth Klarman’s 13F portfolio value decreased from $12.33B to $10.88B this quarter. Baupost Group increased Liberty SiriusXM, Theravance Biopharma, and Joby Aviation while decreasing eBay, Willis Towers Watson, International Flavors & Fragrances, and PG&E. The portfo...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President...
Image source: The Motley Fool. Atara Biotherapeutics, inc (NASDAQ: ATRA) Q3 2021 Earnings Call Nov 4, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcrip...
Atara Biotherapeutics, Inc. (ATRA) Q3 2021 Earnings Conference Call November 04, 2021, 08:30 AM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Jakob Dupont - EVP and Global Head of Research and Development Utpal Koppikar - CFO AJ Joshi - Chie...
Positive New ALLELE Results Show 50% Objective Response Rate (ORR) and Strong Safety Profile Reinforcing Transformative Potential of Tab-cel ® One-year Survival Rate of 89.2% for Patients Responding to Tab-cel Compared with 32.4% Among Non-Responders Long-...
Atara Biotherapeutics (NASDAQ:ATRA): Q3 GAAP EPS of -$0.90 beats by $0.06. Revenue of $5.37M beats by $1.33M. Press Release Cash, cash equivalents and short-term investments as of September 30, 2021 totaled $357.2M, as compared to $373.4M as of June 30, 2021 Atara believes that its cash as of...
Positive Pivotal Phase 3 ALLELE Data Reinforcing the Transformative Potential of Tab-cel ® to be Highlighted as Oral Presentation at Upcoming American Society of Hematology Meeting Significant Tab-cel ® Regulatory Progress with Imminent EU MAA Submission ...
Atara Biotherapeutics (NASDAQ:ATRA) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is -$0.94 and the consensus Revenue Estimate is $4.04M Over the last 3 months, EPS estimates have seen 2 upward revisions and 7 downward. ...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...